BONU BioNeutral Group, Inc. Commences Shipment of its Ogiene-MTM Formulation to Mr. Mold LLC
BioNeutral
Group, Inc. (“BioNeutral”) (OTCBB: BONU stock news), a chemical
technology-based Life Science company that intends to commercialize a
combinational chemistry-based technology, announced today that it has
commenced shipping its Ogiene-MTM formulation, pursuant to
the letter of intent entered into on May 26, 2009 between BioNeutral and Mr.
Mold LLC, a New Jersey based mold remediation company with
operations throughout the northeast.
The Ogiene-MTM formulation removes the odor and stains caused
by mold spores when these spores come in contact with water. Mold spores
are found in most environments. They become activated with water and the
resultant mold can spread quite quickly. The problem is prolific and
affects many of the homes in the southern half of the country,
especially when the temperature rises and the humidity is high. Ogiene-MTM
is used in mold/mildew stain and order elimination to quickly alleviate
these problems and rapidly breaks down into harmless substances making
it a “Green” solution for the environment.
Thomas Re, Founder and CEO of Mr. Mold LLC said, “This is an exciting
time for our company as it provides us an edge over our competitors by
providing a ‘green’ solution to a potentially dangerous and costly
problem of the spread of mold spores. We are looking forward to
utilizing the Ogiene-MTM formulation as soon as possible on
our jobsites as well as informing our customers of a safe alternative to
the traditional toxic solutions that are currently in the marketplace.”
Stephen J. Browand, President and CEO of BioNeutral Group, Inc said,
"Ogiene-MTM is a highly effective product and we intend
to do a significant amount of business with Mr. Mold, their national
affiliates and the customers they serve. We are proud of the attributes
of our formulation being “green” and completely environmentally safe."
About BONUtock Profile BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark,
New Jersey, BioNeutral
Group, Inc., is a chemical technology-based Life Science company
that intends to commercialize a combinational chemistry-based technology
which can neutralize harmful environmental contaminants, toxins and
dangerous micro-organisms including bacteria, viruses, mold, fungi and
spores. The formulations, including Ygiene™ and Ogiene™, which are
eco-friendly and include natural and common ingredients which are found
in baby products and in every day foods. The Company has combined these
widely-used compounds in highly specialized ways to create products that
dramatically enhance disinfecting and cleaning results; products include
BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform
technology has been proven effective in surface, water and airborne
applications.
More information about the Company may be found at www.bioneutralgroup.com
Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its
competitors. The results are published to let shareholders know how the
Company's technology compares with known formulations in the market
place. Any product claim for antimicrobial activity requires approval
from the EPA or FDA, depending upon where and how the formulations are
used. The EPA and FDA have not reviewed or confirmed the Company's data
and findings. BioNeutral's antimicrobial formulations will be marketed
under the brand name Ygiene™ and are not yet available for sale in the
United States.
Under The Private Securities Litigation Reform Act of 1995: The
statements in the press release that relate to the Company's
expectations with regard to the future impact on the Company's results
from new products in development are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
These statements are subject to risks and uncertainties. Words such as
"expects", "intends", "plans", "may", "could", "should", "anticipates",
"likely", "believes" and words of similar import also identify
forward-looking statements. Forward-looking statements are based on
current facts and analyses and other information that are based on
forecasts of future results, estimates of amounts not yet determined and
assumptions of management. Readers are urged not to place undue reliance
on the forward-looking statements, which speak only as of the date of
this release. We assume no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may arise
after the date of this release. Additional information on risks and
other factors that may affect the business and financial results of
BioNeutral Group can be found in the filings of BioNeutral Group with
the U.S. Securities and Exchange Commission.
